Business Context and Reporting Period
This Form 8-K Current Report was filed by Alzamend Neuro, Inc. (ALZN) on May 7, 2024. The report discloses the termination of a material agreement regarding the company's At-the-Market (ATM) equity issuance program.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only financial metrics disclosed relate to the terminated ATM program:
- Total Shares Sold: 1.08 million shares of common stock.
- Gross Proceeds Raised: Approximately $1.3 million.
- Average Price per Share: Approximately $1.20.
Material Changes
On May 6, 2024, the Company provided written notice to Ascendiant Capital Markets, LLC to terminate the ATM Issuance Sales Agreement dated September 8, 2023. The termination is effective as of May 16, 2024. This action halts further sales of common stock under this specific agreement.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to inherent risks and uncertainties. No specific operational guidance or future financial outlook was provided in this document beyond the announcement of the ATM termination.
Investor Verification Checklist
- Verify the effective date of the ATM termination (May 16, 2024) to confirm no further shares can be sold under the September 2023 agreement.
- Review the press release (Exhibit 99.1) for management's rationale regarding the termination.
- Check subsequent filings to determine if the Company intends to enter into a new sales agreement or alternative capital raising strategy.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K, as this filing does not provide current liquidity data.